Advertisement

Letters to the Editor

Imiquimod to Treat Basal Cell and Squamous Cell Carcinomas

Am Fam Physician. 2005 Jul 1;72(01):41.

to the editor: It was good to see the review article1 of basal cell and squamous cell carcinomas. Please note that, since this article was written, imiquimod 5% cream (Aldara) has received approval by the U.S. Food and Drug Administration for the treatment of some types of actinic keratoses and basal cell cancers. It is specifically indicated for the treatment of biopsy-confirmed, primary superficial basal cell carcinoma in immunocompetent adults, with a maximum tumor diameter of 2 cm.2

REFERENCES

1. Stulberg  DL, Crandell  B, Fawcett  RS.  Diagnosis and treatment of basal cell and squamous cell carcinomas.  Am Fam Physician.  2004;70:1481–8.

2. Aldara [package insert]. St. Paul, Minn.: 3M Pharmaceuticals, 2004.

editor’s note: 3M Pharmaceuticals manufactures imiquimod.

 

Send letters to Kenneth W. Lin, MD, Associate Deputy Editor for AFP Online, e-mail: afplet@aafp.org, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680.

Please include your complete address, e-mail address, telephone number, and fax number. Letters should be fewer than 500 words and limited to six references, one table or figure, and three authors.

Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the American Academy of Family Physicians permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.

Article Tools

Printer-friendly

Share this page

AFP CME Quiz

Get Permissions

Search AFP

 

AFP at a Glance
INDUSTRY INFORMATION
Advertisement
Advertisement